Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic transplantation with CD34+-selected cells

M Stockschläder1, H T Hassan, W Zeller

  • 1Bone Marrow Transplantation Unit, University Hospital Eppendorf, Hamburg, Germany.

Leukemia & Lymphoma
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany.

Bone marrow transplantation·2017
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Impact of molecular residual disease post allografting in myelofibrosis patients.

Bone marrow transplantation·2017
Same author

Directly observed daily mouth care provided to care home residents in one area of Kent, UK.

Community dental health·2017
Same author

Cytogenetic Studies in Patients with Acute Myeloid Leukemia Following a Myelodysplastic Syndrome.

Leukemia & lymphoma·2016
Same author

Immunophenotype of Abnormal Metaphases Demonstrating Multilineage Involvement in Myelodysplastic Syndromes.

Leukemia & lymphoma·2016

Allogeneic CD34-selected cell transplantation shows promise for hematological malignancies. This approach, using enriched stem cells, achieved engraftment in most patients, with some developing manageable graft-versus-host disease.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Allogeneic stem cell transplantation is a curative option for hematological malignancies.
  • Myeloablative therapy followed by stem cell rescue is standard practice.
  • Optimizing graft composition, particularly T-cell content, is crucial for reducing graft-versus-host disease (GvHD) and improving outcomes.

Purpose of the Study:

  • To evaluate the safety and efficacy of allogeneic CD34-selected cell transplantation following myeloablative therapy in patients with hematological malignancies.
  • To assess engraftment kinetics, GvHD incidence, and overall survival in this patient cohort.
  • To explore the potential of T-cell depletion via CD34 selection in mitigating GvHD.

Main Methods:

  • Eight patients with hematological malignancies received myeloablative therapy followed by allogeneic CD34-selected cell transplantation.

Related Experiment Videos

  • Graft sources included G-CSF mobilized peripheral blood progenitor cells (PBPC) and/or bone marrow (BM).
  • Engraftment, GvHD, and survival were monitored post-transplantation.

    • Main Results:

    • Seven of eight patients achieved engraftment, with median neutrophil recovery on day 19 and platelet recovery on day 34.
    • Three of seven evaluable patients developed acute GvHD grade II, which resolved with steroid treatment.
    • Five of eight patients survived with a median follow-up of 215 days, with causes of death including infection and bleeding.

    Conclusions:

    • Allogeneic CD34-selected cell transplantation is feasible and can lead to successful engraftment in hematological malignancies post-myeloablation.
    • Preliminary data suggest a potentially reduced incidence or severity of GvHD, but further investigation is needed.
    • The long-term impact of T-cell depletion through CD34 selection on GvHD and graft-versus-leukemia effects requires further study.